The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

Regular insulin, which is often used in pregnancy for the treatment of diabetes, has some drawbacks: it starts its action from 30 to 60 min after subcutaneous injection and it peaks too late (2-3 ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Biocon Biologics and Civica Inc. not-for-profit generic drug and pharmaceutical company founded in 2018 to address and resolve life-saving drug shortages and affordability, has inked a strategic ...

Biocon Biologics Ltd, a fully integrated global biosimilars company and a subsidiary of Biocon, has announced a collaboration with Civica, Inc. Under this agreement, Biocon Biologics will supply ...

Insulin as part (rDNA origin) injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days ...